Collaborations and acquisitions

BT Catalyst,  March-April, 2005  

• E-mail
• Print
• Link

Fourteen collaborations and four acquisitions involving North Carolina biotechnology companies were announced in January and February.

Amphora Discovery, Research Triangle Park, has entered into a multi-year research partnership with Ortho-McNeil Pharmaceutical to discover and develop new treatments for inflammatory disease.

Alveolus, Charlotte, has signed a distribution agreement with BVM Medical, Leicestershire, United Kingdom, a leading reseller of disposable surgical and medical devices.

Asklepios Biopharmaceutical, Chapel Hill, entered into a research collaboration with the Musculoskeletal Transplant Foundation, Edison, N.J., to jointly develop and commercialize novel solutions to orthopedic tissue repair.

Biolex, Pittsboro, signed an agreement with Medarex, Princeton, N.J., to create a commercial line for an unnamed Medarex monoclonal antibody using the Biolex LEX System[R].

Biolex also announced it has entered into a collaboration with OctoPlus, Leiden, The Netherlands, for co-development of a controlled release formulation of recombinant human alfa interferon.

Chelsea Therapeutics, Charlotte, signed a de.nitive deal to combine with Ivory Capital Corp., Colorado, in a reverse merger that will establish Chelsea as a publicly listed company.

CLOSURE Medical Corp., Raleigh, was acquired by Johnson & Johnson in a cash-for-stock exchange worth $370 million.

Cornerstone BioPharma, Cary, and Adams Laboratories, Chester, N.J., have announced a business transaction surrounding the AlleRx[TM] and Humibid[TM] family of products.

Icagen, Research Triangle Park renewed its research and development agreement with Abbott, Abbott Park, Ill., to discover and develop small molecule drugs for the treatment of neuropathic and inflammatory pain.

Icoria, Research Triangle Park, signed an agreement to screen chemicals from DuPont Crop Protection, Wilmington, Del., to identify new agricultural products.

Icoria signed a Cooperative Research and Development Agreement with the U.S. Army Edgewood Chemical Biological Center, Aberdeen Proving Ground, Md., to identify and validate metabolomic biomarkers associated with exposure to low-level chemical warfare agents.

Icoria has licensed to Syngenta the exclusive rights to commercially develop 30 Icoria compounds believed to be active fungal inhibitors.

Kendro Laboratory Products, Asheville, will be acquired by Thermo Electron, Woburn, Mass., for $834 million.

PPD, Wilmington, and CMIC, Tokyo, formed a strategic alliance that will enable PPD to extend its clinical operations and consulting services in Japan. PPD also signed an agreement to acquire the biomarker business of SurroMed, Mountain View, Calif.

Serenex, Durham, signed a broad master agreement with GlaxoSmithKline, Research Triangle Park, to utilize its Proteome Mining technology to elucidate the mechanism-of-action targets and generate broad selectivity information for compounds that GSK is developing.

Synthematix, Durham, will be acquired by Symyx Technologies, Santa Clara, Calif.

A majority control of TherapyEdge, Durham, was acquired by Advanced Biological Laboratories, Luxembourg.

Quintiles, Research Triangle Park, and the University of North Carolina at Chapel Hill announced the creation of a new alliance for clinical research.

COPYRIGHT 2005 North Carolina Biotechnology Center
COPYRIGHT 2008 Gale, Cengage Learning